EGFR NSCLC Learning Lab
Amivantamab plus lazertinib showed a statistically significant improvement in OS compared with osimertinib.
The study, which expanded on phase 3 ADAURA, compared treatment with neoadjuvant osimertinib with or without chemotherapy.
Results demonstrated extended median progression-free survival by nearly 9 months versus standard of care.
The updated data showed an overall survival benefit with osimertinib for treating EGFR-mutated NSCLC.
The trial compared the combination with chemotherapy alone in patients with EGFR exon 20 insertion-mutated advanced NSCLC.
Latest News
Physician's Weekly
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.